AlphaQuest LLC Trims Stock Holdings in Krystal Biotech, Inc. $KRYS

AlphaQuest LLC trimmed its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 65.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 579 shares of the company’s stock after selling 1,084 shares during the period. AlphaQuest LLC’s holdings in Krystal Biotech were worth $80,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brooklyn Investment Group grew its stake in shares of Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock valued at $25,000 after buying an additional 105 shares during the period. Twin Tree Management LP acquired a new stake in Krystal Biotech during the 1st quarter valued at approximately $29,000. Smartleaf Asset Management LLC boosted its stake in Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company’s stock valued at $58,000 after acquiring an additional 177 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in Krystal Biotech during the 1st quarter worth approximately $74,000. Finally, Asset Management One Co. Ltd. acquired a new stake in shares of Krystal Biotech during the second quarter worth $85,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on KRYS. Citigroup raised their target price on Krystal Biotech from $166.00 to $198.00 and gave the company a “neutral” rating in a research note on Tuesday. Bank of America lifted their price target on Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Guggenheim set a $224.00 price objective on shares of Krystal Biotech and gave the stock a “buy” rating in a research note on Friday, October 17th. HC Wainwright reaffirmed a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Monday, September 15th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Krystal Biotech in a research report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $228.14.

Krystal Biotech Price Performance

Shares of KRYS opened at $199.88 on Thursday. The company has a market capitalization of $5.80 billion, a PE ratio of 29.97 and a beta of 0.65. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $212.98. The company’s fifty day moving average price is $172.56 and its 200 day moving average price is $153.49.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $1.54. The company had revenue of $97.80 million for the quarter, compared to the consensus estimate of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. Analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).